Press Release
In a COLO-205 xenograft model, ACT-903 demonstrates tumor suppression, increased survival after single and multiple doses, and no signs of toxicityToronto, Canada, May 26, 2022 — Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, announced details from the company’s abstract published today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO meeting will be held in Chicago from June 3-8, 2022.
View Full Press Release